What is he best known for?
The fields of study he is best known for:
- Acquired immunodeficiency syndrome
- Internal medicine
- Immune system
Edwin DeJesus mainly focuses on Internal medicine, Pharmacology, Emtricitabine, Viral load and Efavirenz.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Lamivudine and Ritonavir.
The various areas that he examines in his Lamivudine study include Reverse-transcriptase inhibitor and Acquired immunodeficiency syndrome, Zidovudine.
His research in Pharmacology intersects with topics in Cobicistat and Confidence interval.
The study incorporates disciplines such as Integrase inhibitor and Elvitegravir in addition to Emtricitabine.
Edwin DeJesus has included themes like Placebo, HIV tropism, CCR5 receptor antagonist and Maraviroc in his Viral load study.
His most cited work include:
- Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study (2421 citations)
- Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. (1233 citations)
- The major genetic determinants of HIV-1 control affect HLA class I peptide presentation (910 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Emtricitabine, Pharmacology, Regimen and Ritonavir.
His Internal medicine research includes elements of Gastroenterology, Lamivudine, Efavirenz and Viral load.
His Lamivudine research incorporates elements of Reverse-transcriptase inhibitor and Zidovudine.
His studies deal with areas such as Elvitegravir, Tenofovir alafenamide, Randomized controlled trial, Cobicistat and Raltegravir as well as Emtricitabine.
His Pharmacology research is multidisciplinary, incorporating perspectives in Placebo and Discontinuation.
His work carried out in the field of Regimen brings together such families of science as Protease inhibitor and Chemotherapy.
He most often published in these fields:
- Internal medicine (62.22%)
- Emtricitabine (38.89%)
- Pharmacology (37.78%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (62.22%)
- Emtricitabine (38.89%)
- Tenofovir alafenamide (15.56%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Emtricitabine, Tenofovir alafenamide, Regimen and Randomized controlled trial.
His biological study spans a wide range of topics, including Gastroenterology, Placebo, Lamivudine and Viral load.
His Viral load research is multidisciplinary, incorporating elements of Cobicistat and Oncology.
His studies in Emtricitabine integrate themes in fields like Efavirenz, Tolerability, Darunavir and Ritonavir.
His Tenofovir alafenamide study also includes
- Bictegravir which intersects with area such as Pharmacology,
- Dolutegravir and related Fixed-dose combination and Hepatitis C.
His Regimen study incorporates themes from Protease inhibitor, Tenofovir, FCGR2B, Urology and HIV vaccine.
Between 2016 and 2021, his most popular works were:
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial (127 citations)
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial (58 citations)
- Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. (56 citations)
In his most recent research, the most cited papers focused on:
- Acquired immunodeficiency syndrome
- Internal medicine
- Immune system
Emtricitabine, Internal medicine, Tenofovir alafenamide, Randomized controlled trial and Regimen are his primary areas of study.
His Internal medicine research is mostly focused on the topic Adverse effect.
The Adverse effect study combines topics in areas such as Rilpivirine and Viral load.
In his research on the topic of Randomized controlled trial, Pharmacology is strongly related with Bictegravir.
His study in Regimen is interdisciplinary in nature, drawing from both Darunavir and Tenofovir.
Edwin DeJesus has researched Darunavir in several fields, including Surgery, Lamivudine, Abacavir, Reverse-transcriptase inhibitor and Ritonavir.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
